Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare ...

Biogen Inc. raised its full-year financial guidance as growing sales of its Alzheimer’s drug helped the biotech company beat ...

Biogen Inc. has announced a $2 billion investment to expand its manufacturing capabilities at Research Triangle Park (RTP), ...

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Biogen’s Qalsody (tofersen) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the first ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...

Biogen will invest $2 billion more in its existing manufacturing plants in North Carolina, the drugmaker said on Monday, as ...